Sunday, August 17, 2025 8/17/2025

MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC

Award Number: U24CA224285
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC - ABSTRACT Immunotherapy (IMT) has emerged as a promising treatment strategy across a broad spectrum of human cancers, with multiple agents, particularly immune check point inhibitors, showing promising results in various types of cancers. Its full potential has yet to be realized, due in part, to a lack of biomarkers predicting response to treatment. Multiple immune and genomic biomarkers of response based on analysis of pre-treatment specimens have been described but most are not very robust with significant overlap between responders and non-responders. Therefore, there is a critical unmet need to perform comprehensive characterization of candidate biomarkers in early phase IMT trials using standardized assays and novel methodologies. Recognizing the need for comprehensive immune monitoring for IMT clinical trials, in 2017 NCI developed the Cancer Immune Monitoring and Analysis Center (CIMAC) and Cancer Immunologic Data Commons (CIDC) Network, with the goal of identifying biomarkers of response, resistance, and adverse events to optimize immunotherapy approaches for patients with cancer. The MD Anderson Cancer Immune Monitoring and Analysis Center (MDA-CIMAC) is one of four CIMAC sites established five years ago that has been standardizing genomic, pathology and immunology assays and supporting profiling of tissue and blood specimens from patients treated in IMT trials. The MDA-CIMAC will be co-led by Drs. Ignacio Wistuba, renowned cancer surgical and molecular pathologist, Gheath Al-Atrash, well-known medical oncologist with expertise in stem cell transplantation and immunotherapy, and Cara Haymaker, cancer immunologist with expertise in immune biomarker analysis. They will be supported by a multidisciplinary team of world-class and highly collaborative experts on cancer and immunotherapy. The main goals of MDA-CIMAC are to: 1) provide a centralized and harmonized platform for sample collection, processing and quality assurance, and 2) use analytically-validated and standardized (Tiers 1 and 2) and highly innovative (Tier 3) assays to offer analyses for phenotypic, genomic, and functional characterization of responses of patients enrolled on IMT clinical trials. In Aim 1, we will utilize Standard Operating Procedures (SOPs) following the developed CIMAC umbrella protocol to provide services for processing and distribution of annotated biospecimens from the NCI-sponsored early phase immunotherapy clinical trials and to link the specimens to relevant clinical, pathological, immune and molecular data within the CIMAC-CIDC Network. In Aim 2, we will perform routine and innovative pathological, immunological and molecular analyses using standardized and validated and highly innovative assays to aid the completion of NCI- sponsored early phase clinical trials and the development of novel predictive IMT biomarkers. In Aim 3, in conjunction with the CIDC team, we will provide biostatistics and computational services for data collection and analysis, and will perform, interpret and predict modeling of high dimensional (‘omic”) data. We envision that the MDA-CIMAC will be indispensable as we make meaningful progress in cancer immunotherapeutic approaches.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,924,560 )
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	4	8/11/2025	NON-COMPETING CONTINUATION	$1,924,560
														Subtotal = $1,924,560

Issue Date FY: 2024 ( Subtotal = $1,828,332 )
2024	2024	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	004	3	8/30/2024	NON-COMPETING CONTINUATION	$1,749,597
2024	2024	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	003	3	7/2/2024	NON-COMPETING CONTINUATION	$78,735
2024	2023	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	11/1/2023	COMPETING CONTINUATION	$2,790,698
2024	2017	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	11/1/2023	NEW	-$2,790,698
2024	2017	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	002	1	11/2/2023	NEW	$0
														Subtotal = $1,828,332

Issue Date FY: 2023 ( Subtotal = $1,924,560 )
2023	2023	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	8/10/2023	COMPETING CONTINUATION	$1,924,560
2023	2023	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	8/16/2023	COMPETING CONTINUATION	$0
														Subtotal = $1,924,560

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2017	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	1	7/21/2022	NEW	$0
2022	2017	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	12/16/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	2/10/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2017	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	9/10/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $11,005,230 )
2017	2017	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	9/25/2017	NEW	$11,005,230
														Subtotal = $11,005,230

Grand Total All Awards = $16,682,682

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC

Award Number: U24CA224285

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer